Literature DB >> 9876628

Enhancement of bioavailability of griseofulvin by its complexation with beta-cyclodextrin.

M D Dhanaraju1, K S Kumaran, T Baskaran, M S Moorthy.   

Abstract

Griseofulvin is a poorly soluble antifungal antibiotic drug, the solubility of which can be enhanced by complexation with beta-cyclodextrin. The inclusion complex was prepared by coprecipitation method in various molar ratios of 1:1, 2:1, 3:1, and 1:2 of the drug and beta-cyclodextrin, respectively. The inclusion complex was characterized and evaluated by UV-VIS spectral studies and FTIR. The in vitro drug release studies indicated that the 1:2 molar ratio complex form of the drug significantly increased the dissolution rate when compared to the free form. The acute toxicity studies clearly indicated that the beta-cyclodextrin complex was nontoxic and the safety range was close to other Griseofulvin formulations. The in vivo study of the beta-cyclodextrin was carried out in both animals and human beings by administering in four different rabbits and volunteers, respectively. Pellets made with Griseofulvin-beta-cyclodextrin complex also showed a significant increase in the dissolution of the drug, revealing that beta-cyclodextrin plays an important role in the solubilization of Griseofulvin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9876628     DOI: 10.3109/03639049809085663

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  10 in total

Review 1.  Impact of excipient interactions on drug bioavailability from solid dosage forms.

Authors:  Ravikiran Panakanti; Ajit S Narang
Journal:  Pharm Res       Date:  2012-05-19       Impact factor: 4.200

2.  Bioadhesive microspheres for bioavailability enhancement of raloxifene hydrochloride: formulation and pharmacokinetic evaluation.

Authors:  Ram K Jha; Sanjay Tiwari; Brahmeshwar Mishra
Journal:  AAPS PharmSciTech       Date:  2011-05-12       Impact factor: 3.246

3.  Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses.

Authors:  Edwin Chiu Yuen Chow; Arjang Talattof; Eleftheria Tsakalozou; Jianghong Fan; Liang Zhao; Xinyuan Zhang
Journal:  AAPS J       Date:  2016-08-12       Impact factor: 4.009

4.  Aerosolization, Drug Permeation and Cellular Interaction of Dry Powder Pulmonary Formulations of Corticosteroids with Hydroxypropyl-β-Cyclodextrin as a Solubilizer.

Authors:  Ville Vartiainen; Luis M Bimbo; Jouni Hirvonen; Esko I Kauppinen; Janne Raula
Journal:  Pharm Res       Date:  2016-09-07       Impact factor: 4.200

Review 5.  Cyclodextrins in drug delivery: an updated review.

Authors:  Rajeswari Challa; Alka Ahuja; Javed Ali; R K Khar
Journal:  AAPS PharmSciTech       Date:  2005-10-14       Impact factor: 3.246

6.  Study of the Complexation Behaviour of Fexofenadine with β-Cyclodextrin.

Authors:  Nidhi P Sapkal; Vaishali A Kilor; Bharti D Shewale; K P Bhusari; A S Daud
Journal:  Indian J Pharm Sci       Date:  2010-05       Impact factor: 0.975

Review 7.  Nanosizing of drugs: Effect on dissolution rate.

Authors:  S Maleki Dizaj; Zh Vazifehasl; S Salatin; Kh Adibkia; Y Javadzadeh
Journal:  Res Pharm Sci       Date:  2015 Mar-Apr

8.  Investigation of molecular aggregation mechanism of glipizide/cyclodextrin complexation by combined experimental and molecular modeling approaches.

Authors:  Tianhe Huang; Qianqian Zhao; Yan Su; Defang Ouyang
Journal:  Asian J Pharm Sci       Date:  2018-12-08       Impact factor: 6.598

9.  Influence of the Encapsulation Efficiency and Size of Liposome on the Oral Bioavailability of Griseofulvin-Loaded Liposomes.

Authors:  Sandy Gim Ming Ong; Long Chiau Ming; Kah Seng Lee; Kah Hay Yuen
Journal:  Pharmaceutics       Date:  2016-08-26       Impact factor: 6.321

10.  Formulation and evaluation of cyclodextrin-based nanosponges of griseofulvin as pediatric oral liquid dosage form for enhancing bioavailability and masking bitter taste.

Authors:  Samia M Omar; Fares Ibrahim; Aliaa Ismail
Journal:  Saudi Pharm J       Date:  2020-02-03       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.